CS
ZVRA icon

Credit Suisse’s Zevra Therapeutics ZVRA Stock Holding History

Credit Suisse’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16
Closed – – 4342
2022
Q2 		$0 Buy
+16
New +$73 ﹤0.01% 4373
2016
Q3 		– Sell
-647
Closed -$41K – 4284
2016
Q2 		$41K Sell
647
-1,508
-70% -$248K ﹤0.01% 4161
2016
Q1 		$500K Buy
2,155
+1,484
+221% +$359K ﹤0.01% 3237
2015
Q4 		$213K Buy
+671
New +$182K ﹤0.01% 3857

Other funds holding ZVRA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Credit Suisse's ZVRA Position: Q3 2022 in Review

Credit Suisse sold out of Zevra Therapeutics (ZVRA) in Q3 2022, closing a stake of 16 shares.

Credit Suisse first reported a position in ZVRA in Q4 2015 and held it in 4 quarters. The position peaked at $500K in Q1 2016. 69 funds tracked by Wall St. Rank hold ZVRA as of Q3 2022.

  • Credit Suisse reported no remaining Zevra Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 16 Zevra Therapeutics shares in Q3 2022.
  • Credit Suisse first reported a position in Zevra Therapeutics in Q4 2015 and held it in 4 quarters.
  • Credit Suisse's Zevra Therapeutics position peaked at $500K in Q1 2016.
  • 69 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.